LOGIN  |  REGISTER
Viking Therapeutics

Encompass Health announces date of 2022 fourth quarter earnings call

January 11, 2023 | Last Trade: US$120.58 2.05 -1.67

BIRMINGHAM, Ala., Jan. 11, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its fourth quarter ended Dec. 31, 2022, after the market closes on Feb. 7, 2023. The Company will host an investor conference call at 10 a.m. ET on Feb. 8, 2023, to discuss its results.

The conference call may be accessed by dialing 800-245-3047 and giving the conference ID EHCQ422. International callers should dial 203-518-9765 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media Contact:
Casey Winger | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page